Necrotizing Fasciitis Market is Growing at a Speedy CAGR of 6.2% During Forecast 2017-2023
Necrotizing Fasciitis Market – Insights
The Global Necrotizing Fasciitis Market is expected to grow at a
CAGR of 6.2% during the forecasted
period.
The Global Necrotizing Fasciitis Market is
expecting a steady growth during the forecasted period. Necrotizing fasciitis
is a bacterial infection that affects tissue beneath the skin, surrounding
muscles, and organs. Growing geriatric population, increasing prevalence of
infectious diseases and technological advancement in surgery has driven the
market growth. Moreover, increasing healthcare expenditure, and rising demand
for the better treatment has fueled the growth of the market. However, lack of
awareness about the disease in developing economies and poor reimbursement
policies in developed countries may slow the growth of this market.
Necrotizing Fasciitis Market - Key Players
·
Merck
& Co. (U.S.)
·
WOCKHARDT
(India)
·
Atox
Bio (Israel)
·
Teva
Pharmaceutical Industries (Israel)
·
Basilea
Pharmaceutica Ltd. (Switzerland)
·
MELINTA
THERAPEUTICS, INC. (U.S.)
Necrotizing Fasciitis Market - Segmentation
·
The
Global Necrotizing Fasciitis Market is segmented on the basis of pathogen,
types, treatment, and end users.
·
On
the basis of the type, the market is categorized into Type I, Type II, Type III
and others.
·
On
the basis of the treatment, the market is segmented into intravenous
antibiotics, surgery, hyperbaric oxygen treatment, and others.
·
On
the basis of the end users, the market is segmented into hospitals &
clinics, surgical centers, and others.
Necrotizing Fasciitis Market - Regional Analysis
The
Americas dominate the global Necrotizing Fasciitis Market owing to the presence
of population suffering from bacterial infection and increasing number of
surgical procedures in the hospitals. America is further segmented into North
America and South America. North America holds the largest market owing to
extensive use of advanced technology and developed pharmaceutical sector.
Europe
accounts for the second largest market due to increasing funds, government
support and increasing healthcare expenditure. Germany, France, and the U.K
hold a significant share in the market owing to increasing demand of
technologically advanced devices for the surgical procedures and overall growth
of medical device industry.
Asia
Pacific is the fastest growing market for the necrotizing fasciitis, whose
growth is attributed to rising geriatric population, increasing prevalence of
people suffering from bacterial infections and rapidly developing economies.
Additionally, increasing healthcare expenditure and demand for new treatment
options for rare diseases fuel the market growth. India and China are the major
contributors to the market growth due to the rapid development of healthcare
sector in these regions and increasing demand for diagnostic services.
On
the other hand, the Middle East & Africa is expected witness limited growth
due to limited access to the healthcare resources and lack of awareness about
rare diseases. In the Middle East, the growth of the Necrotizing Fasciitis Market is driven by increasing availability
new diagnostic and treatment methods for various chronic and acute bacterial
infections.
Comments
Post a Comment